Should You Buy Cytokinetics Inc (CYTK) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Buy
Latest Price
65.140
1 Day change
1.77%
52 Week Range
70.980
Analysis Updated At
2026/01/28
Buy now for a long-term beginner. The chart is in a clear uptrend (bullish MA stack and expanding positive MACD), options positioning is strongly call-skewed (risk-on sentiment), and Wall Street has broadly raised targets on the back of FDA approval and improving commercial outlook for Myqorzo. Given you’re impatient and not waiting for an “ideal” dip, CYTK is a good buy at current levels (~65), with near-term upside tied to launch traction and upcoming clinical/earnings catalysts.
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): No signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Technical Analysis
Trend is bullish. Price is holding above key moving averages with a bullish alignment (SMA_5 > SMA_20 > SMA_200), which typically signals sustained upside momentum. MACD histogram is positive (0.108) and expanding, supporting continuation. RSI(6) ~61 is neutral-to-slightly-bullish (not overbought).
Key levels: Pivot 63.63 is the near-term line to hold. Immediate resistance is R1 65.50 (very close to current price) and then R2 66.65; a push/close above these levels would confirm further upside. Supports are S1 61.77 and S2 60.62.
Pattern-based forward bias (provided): ~0.87% next day, ~5.04% next week, ~8.41% next month (probabilistic, not guaranteed).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Options sentiment is notably bullish: put-call ratios are very low (OI PCR 0.21; Volume PCR 0.27), indicating traders are positioning more aggressively in calls than puts. Implied volatility is elevated (30D IV ~69.34 vs historical vol ~46.08), suggesting the market is pricing meaningful moves. Volume today (504) is below its 5D/10D averages, but open interest is large (total OI ~119,649; call OI ~98,608 vs put OI ~21,041), reinforcing a call-heavy structure.
Technical Summary
Sell
2
Buy
9
Positive Catalysts
2026/01/28 17:01:25
1) FDA approval of aficamten as Myqorzo for symptomatic obstructive hypertrophic cardiomyopathy, with commentary emphasizing a differentiated label/REMS profile versus Camzyos.
2) Commercial launch traction narrative: analyst notes cite strong early uptake and formulary progress.
3) Clinical catalyst: Phase 3 ACACIA (non-obstructive HCM) readout expected early 2Q26 (per analyst commentary), which could expand market opportunity.
4) Upcoming event: QDEC 2025 earnings on 2026-02-25 after hours (potential updates on launch metrics and guidance).
Neutral/Negative Catalysts
2026/01/28 17:01:25
1) Hedge funds selling: reported selling increased sharply over the last quarter (risk of overhead supply).
2) Legal overhang: investigation into potential fiduciary duty breaches (2026-01-22), which can pressure sentiment.
3) Elevated implied volatility implies the market expects large swings; if launch metrics or upcoming updates disappoint, downside could be fast.
Financial Performance
Latest quarter provided: 2025/Q3. Revenue rose to $1.936M (+318.14% YoY), indicating improving top-line contribution (still small base). Losses improved versus prior year: net income was -$306.178M (90.71% YoY improvement) and EPS was -$2.55 (87.50% YoY improvement). Overall: growth is moving in the right direction (revenue accelerating and losses narrowing), consistent with a company transitioning toward commercialization, but profitability is not yet present.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent analyst trend is decisively positive: multiple firms raised price targets and reiterated Buy/Overweight/Outperform following FDA approval and improved commercial outlook. Notable updates include: B. Riley raised PT to $108 (Buy), Morgan Stanley raised to $90 (Overweight), Barclays initiated/maintained Overweight with $87, Leerink moved to $83 (Outperform), Truist to $84 (Buy), and H.C. Wainwright to $136 (Buy). The main “pro” view: Myqorzo is differentiated (label/REMS/titration flexibility) and can compete effectively vs Camzyos with meaningful peak-sales potential; upcoming trial data could further expand the story. The main “con” view (minority): some skepticism that approval/label changes the debate materially (e.g., BofA Neutral with $64), implying valuation and execution/launch traction remain key swing factors.
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61 USD and a high forecast of 136 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
Wall Street analysts forecast CYTK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CYTK is 89.33 USD with a low forecast of 61 USD and a high forecast of 136 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 64.010
Low
61
Averages
89.33
High
136
Current: 64.010
Low
61
Averages
89.33
High
136
Barclays
Hang Hu
Overweight
initiated
$87
AI Analysis
2026-01-28
New
Reason
Barclays
Hang Hu
Price Target
$87
AI Analysis
2026-01-28
New
initiated
Overweight
Reason
Barclays analyst Hang Hu assumed coverage of Cytokinetics with an Overweight rating and $87 price target. The firm says that given a "differentiated" label with flexibility of titration, it continues to view Myqorzo as a preferred drug over Camzyos in obstructive hypertrophic cardiomyopathy.
B. Riley
B. Riley
Buy
maintain
$90 -> $108
2026-01-21
Reason
B. Riley
B. Riley
Price Target
$90 -> $108
2026-01-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Cytokinetics to $108 from $90 and keeps a Buy rating on the shares. Recent Myqorzo launch metrics show strong early uptake, with over 50% new patient share among roughly 700 high-volume HCPs by YE26 and formulary parity achieved despite a modest wholesale acquisition cost premium to Camzyos, positioning the product to compete on Risk Evaluation and Mitigation Strategy differentiation rather than price, the analyst tells investors in a research note. Near-term focus is on the Phase 3 ACACIA Non-obstructive Hypertrophic Cardiomyopathy readout expected in early 2Q26, which could drive a halo effect in hypertrophic cardiomyopathy share capture, supported by a higher-dose, faster titration protocol and rigorous patient selection that improve on prior peer trial outcomes, the firm says.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CYTK
